EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca

Mohamed Hassan Nasraa iD, Dina Nadeem Abd-Elshafy, Rola Nadeem, Said Shalaby, Khaled Amer, Wael Ali Hassan, Ahmed Hamdy Bader, Hasnaa A Elshehaby, Mahmoud Mohamed Bahgat

Viral Immunology · 01.10.2026 · 39 (8) · 293-304

DOI: 10.1177/08828245261474281 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Viral Immunology, online erschienen am 07.08.2026. Verfasst von Mohamed Hassan Nasraa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Group Immune- and Bio-markers for Infection, the Centre of Excellent for Advanced Science, the National Research Centre, Giza, Egypt. Hauptthemen laut MEDLINE: Antibodies, Viral, SARS-CoV-2, Immunity, Humoral, Spike Glycoprotein, Coronavirus. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The diversity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine platforms and widespread natural exposure have created a complex landscape of humoral immunity requiring detailed characterization. Here, we compare nucleocapsid (N)- and spike (S)-specific antibody responses in sera from infected humans (IH) during the first pandemic wave (April–August 2020) and in vaccine recipients (Sinopharm, Sinovac, or AstraZeneca) using commercial ELISA kits. Among naturally IH, the IgG-positivity rate was higher for N (80.9%) than S (42.8%), with significantly elevated N-specific IgG levels compared to prepandemic controls ( p -value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralSARS-CoV-2Immunity, HumoralSpike Glycoprotein, CoronavirusCOVID-19COVID-19 VaccinesCoronavirus Nucleocapsid ProteinsHumansImmunoglobulin GImmunoglobulin MFemaleVaccinationMale

Stichwörter der Autor:innen

humoral immunityprotectionvaccines

Substanzen

Antibodies, ViralImmunoglobulin GSpike Glycoprotein, CoronavirusImmunoglobulin MCOVID-19 Vaccinesspike protein, SARS-CoV-2Coronavirus Nucleocapsid Proteins

Autor:innen und Institutionen

  • Research Group Immune- and Bio-markers for Infection, the Centre of Excellent for Advanced Science, the National Research Centre, Giza, Egypt.
  • Department of Therapeutic Chemistry, Institute of Pharmaceutical and Drug Industries Research, the National Research Centre, Dokki, Egypt.
  • Environmental Virology Laboratory, Department of Water Pollution Research, Institute of Environmental Research and Climate Changes, the National Research Centre, Giza, Egypt.
  • Department of Complementary and Alternative Medicine, Medical Research Institute, National Research Centre, Giza, Egypt.
  • Egypt Center for Research and Regenerative Medicine, Cairo, Egypt.

ORCID-Profile: Mohamed Hassan Nasraa

Zitieren

APA

Nasraa, M. H., Abd-Elshafy, D. N., Nadeem, R., Shalaby, S., Amer, K., Hassan, W. A., Bader, A. H., Elshehaby, H. A., & Bahgat, M. M. (2026). Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca. Viral Immunology, 39(8), 293-304. https://doi.org/10.1177/08828245261474281

Vancouver

Nasraa MH, Abd-Elshafy DN, Nadeem R, Shalaby S, Amer K, Hassan WA, et al. Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca. Viral Immunology. 2026;39(8):293-304. doi:10.1177/08828245261474281

BibTeX
@article{Nasraa2026,
  author = {Nasraa, Mohamed Hassan and Abd-Elshafy, Dina Nadeem and Nadeem, Rola and Shalaby, Said and Amer, Khaled and Hassan, Wael Ali and Bader, Ahmed Hamdy and Elshehaby, Hasnaa A and Bahgat, Mahmoud Mohamed},
  title = {Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca},
  journal = {Viral Immunology},
  year = {2026},
  volume = {39},
  number = {8},
  pages = {293--304},
  doi = {10.1177/08828245261474281}
}
Kostenlos starten →